Regulus Therapeutics Inc.
RGLS
$7.87
-$0.005-0.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 6.82M | 33.26M | 1.02M | 8.31M | 6.04M |
| Gross Profit | -6.82M | -33.26M | -1.02M | -8.31M | -6.04M |
| SG&A Expenses | 3.72M | 4.07M | 3.86M | 3.95M | 2.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.54M | 13.75M | 15.21M | 12.26M | 8.83M |
| Operating Income | -10.54M | -13.75M | -15.21M | -12.26M | -8.83M |
| Income Before Tax | -9.63M | -12.79M | -14.06M | -11.04M | -8.47M |
| Income Tax Expenses | -- | 0.00 | -- | 1.00K | -- |
| Earnings from Continuing Operations | -9.63M | -12.79M | -14.06M | -11.04M | -8.47M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.63M | -12.79M | -14.06M | -11.04M | -8.47M |
| EBIT | -10.54M | -13.75M | -15.21M | -12.26M | -8.83M |
| EBITDA | -10.45M | -13.66M | -15.12M | -12.17M | -8.75M |
| EPS Basic | -0.15 | -0.20 | -0.21 | -0.17 | -0.29 |
| Normalized Basic EPS | -0.09 | -0.12 | -0.13 | -0.11 | -0.18 |
| EPS Diluted | -0.15 | -0.20 | -0.21 | -0.17 | -0.29 |
| Normalized Diluted EPS | -0.09 | -0.12 | -0.13 | -0.11 | -0.18 |
| Average Basic Shares Outstanding | 66.17M | 65.50M | 65.47M | 64.47M | 28.75M |
| Average Diluted Shares Outstanding | 66.17M | 65.50M | 65.47M | 64.47M | 28.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |